170 related articles for article (PubMed ID: 34081897)
1. Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result.
Strang THR; Gottschlich A; Cook DA; Smith LW; Gondara L; Franco EL; van Niekerk DJ; Ogilvie GS; Krajden M
Am J Obstet Gynecol; 2021 Nov; 225(5):511.e1-511.e7. PubMed ID: 34081897
[TBL] [Abstract][Full Text] [Related]
2. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
3. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
4. Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort.
Gottschlich A; van Niekerk D; Smith LW; Gondara L; Melnikow J; Cook DA; Lee M; Stuart G; Martin RE; Peacock S; Franco EL; Coldman A; Krajden M; Ogilvie G
Cancer Epidemiol Biomarkers Prev; 2021 Jan; 30(1):22-29. PubMed ID: 33082202
[TBL] [Abstract][Full Text] [Related]
5. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
[TBL] [Abstract][Full Text] [Related]
6. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
7. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study.
Castle PE; Rodríguez AC; Burk RD; Herrero R; Wacholder S; Alfaro M; Morales J; Guillen D; Sherman ME; Solomon D; Schiffman M;
BMJ; 2009 Jul; 339():b2569. PubMed ID: 19638649
[TBL] [Abstract][Full Text] [Related]
8. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.
Rebolj M; Cuschieri K; Mathews CS; Pesola F; Denton K; Kitchener H;
BMJ; 2022 May; 377():e068776. PubMed ID: 35640960
[TBL] [Abstract][Full Text] [Related]
9. Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial.
Elfgren K; Elfström KM; Naucler P; Arnheim-Dahlström L; Dillner J
Am J Obstet Gynecol; 2017 Mar; 216(3):264.e1-264.e7. PubMed ID: 27825977
[TBL] [Abstract][Full Text] [Related]
10. Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.
Loopik DL; Koenjer LM; Siebers AG; Melchers WJG; Bekkers RLM
Am J Obstet Gynecol; 2021 Feb; 224(2):200.e1-200.e9. PubMed ID: 32800820
[TBL] [Abstract][Full Text] [Related]
11. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands.
Dijkstra MG; van Zummeren M; Rozendaal L; van Kemenade FJ; Helmerhorst TJ; Snijders PJ; Meijer CJ; Berkhof J
BMJ; 2016 Oct; 355():i4924. PubMed ID: 27702796
[TBL] [Abstract][Full Text] [Related]
12. The 5-year risk of recurrence of grade 2/3 cervical intraepithelial neoplasia after treatment in a population screening programme by human papillomavirus status: A cohort study in central Italy.
Visioli CB; Iossa A; Gorini G; Mantellini P; Lelli L; Auzzi N; Pierro CD; Carozzi FM; Zappa M
J Med Screen; 2023 Dec; 30(4):191-200. PubMed ID: 37229655
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus testing as triage for atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions: sensitivity, specificity, and cost-effectiveness.
Kaufman RH; Adam E; Icenogle J; Reeves WC
Am J Obstet Gynecol; 1997 Oct; 177(4):930-6. PubMed ID: 9369847
[TBL] [Abstract][Full Text] [Related]
14. Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection.
Schneider A; Zahm DM; Kirchmayr R; Schneider VL
Am J Obstet Gynecol; 1996 May; 174(5):1534-41. PubMed ID: 9065125
[TBL] [Abstract][Full Text] [Related]
15. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
16. Incomplete excision of cervical intraepithelial neoplasia as a predictor of the risk of recurrent disease-a 16-year follow-up study.
Alder S; Megyessi D; Sundström K; Östensson E; Mints M; Belkić K; Arbyn M; Andersson S
Am J Obstet Gynecol; 2020 Feb; 222(2):172.e1-172.e12. PubMed ID: 31473226
[TBL] [Abstract][Full Text] [Related]
17. Triage of low-grade squamous intraepithelial lesions using human papillomavirus messenger ribonucleic acid tests-A prospective population-based register study.
Reinholdt K; Juul KE; Dehlendorff C; Munk C; Kjaer SK; Thomsen LT
Acta Obstet Gynecol Scand; 2020 Feb; 99(2):204-212. PubMed ID: 31562779
[TBL] [Abstract][Full Text] [Related]
18. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
Kjær SK; Frederiksen K; Munk C; Iftner T
J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
[TBL] [Abstract][Full Text] [Related]
19. Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening.
Coldman AJ; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan DJ; Lee M; Elwood-Martin R; Gentile L; Peacock S; Stuart GCE; Franco EL; Ogilvie GS
Int J Cancer; 2020 Apr; 146(7):1810-1818. PubMed ID: 31245842
[TBL] [Abstract][Full Text] [Related]
20. Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.
Sørbye SW; Fismen S; Gutteberg TJ; Mortensen ES; Skjeldestad FE
BMJ Open; 2016 Aug; 6(8):e011981. PubMed ID: 27515759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
